New study explores blood, skin, and nasal swabs to spot Parkinson's early
NCT ID NCT07480187
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking for better ways to diagnose Parkinson's disease using samples that are easy to collect, like blood, skin, and nasal swabs. Researchers will compare these samples from 340 people, including those with Parkinson's, Alzheimer's, and healthy volunteers. The goal is to find biological markers that could lead to a simpler, more accurate diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, non-invasive test for Parkinson's disease, enabling earlier diagnosis and better clinical trials.
- What could go wrong
- This is an observational study, not a treatment trial. The biomarkers may not prove accurate enough for widespread use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
340 people
The number who actually took part.
- Started
-
May 2023
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: patients with clinical diagnosis of Parkinson's disease, atypical parkinsonisms, Alzheimer's disease, healthy volunteers, people with subjective cognitive decline. Exclusion Criteria: Other acute neurological diseases or neurodegenerative diseases such as Frontotemporal dementia, vascular dementia, and stroke Relevant comorbidities: chronic kidney disease (significant alteration of blood biomarkers) Skin biopsy: local skin infection at biopsy site, severe dermatologic disease at sampling area, known bleeding disorder, significant thrombocytopenia, anticoagulation not safely manageable, allergy to local anesthetics, poor wound healing, severe peripheral vascular disease, high-risk immunosuppression, inability to consent or cooperate, extensive scarring at intended site Magnetic resonance spectroscopy: non-MRI-compatible implanted device, ferromagnetic intracranial clip, metallic foreign body, severe claustrophobia not manageable, inability to remain still, MRI-conditional device not meeting safety conditions, pregnancy per institutional policy, severe agitation or confusion, body size exceeding scanner limits, severe motion disorder affecting acquisition Venipuncture: refusal or inability to consent, local infection at puncture site, severe coagulopathy, marked thrombocytopenia, high bleeding risk anticoagulation, severe anemia relative to planned blood volume, difficult venous access, history of severe vasovagal syncope Eligibility Criteria Inclusion Criteria: Adults able to provide informed consent Clinical diagnosis of Parkinson's disease Clinical diagnosis of atypical parkinsonism Clinical diagnosis of Alzheimer's disease Individuals with subjective cognitive decline Healthy volunteers Exclusion Criteria: Acute neurological diseases Other neurodegenerative diseases not included in the study groups (e.g., frontotemporal dementia, vascular dementia) History of stroke with significant neurological sequelae Chronic kidney disease with significant alteration of blood biomarkers Procedure-specific exclusion criteria Skin biopsy: Local skin infection at biopsy site Severe dermatologic disease at sampling area Known bleeding disorder Significant thrombocytopenia Anticoagulation not safely manageable Allergy to local anesthetics Poor wound healing Severe peripheral vascular disease High-risk immunosuppression Inability to consent or cooperate Extensive scarring at intended biopsy site Magnetic resonance spectroscopy (MRS): Non-MRI-compatible implanted device Ferromagnetic intracranial clip Metallic foreign body incompatible with MRI Severe claustrophobia not manageable with standard procedures Inability to remain still during MRI acquisition MRI-conditional device not meeting safety conditions Pregnancy according to institutional MRI safety policy Severe agitation or confusion preventing examination Body size exceeding scanner limits Severe motion disorder affecting acquisition Venipuncture: Refusal or inability to provide consent Local infection at puncture site Severe coagulopathy Marked thrombocytopenia High bleeding risk due to anticoagulation Severe anemia relative to planned blood draw volume Difficult venous access History of severe vasovagal syncope during venipuncture Lumbar puncture: Signs of increased intracranial pressure due to mass lesion Local infection at puncture site Uncorrected coagulopathy Severe thrombocytopenia Anticoagulation not safely interruptible Spinal cord compression Unstable spine Refusal or inability to cooperate with the procedure Severe spinal deformity Prior lumbar surgery complicating access Severe anxiety or intolerance to the procedure Pregnancy requiring procedural precautions Nasal brushing: Significant nasal polyposis Severe septal deviation preventing access to the olfactory cleft Active acute or chronic rhinosinusitis Recent epistaxis or bleeding-prone nasal mucosa Nasal lesions, ulcers, or tumors Recent nasal surgery Nasal brushing: Significant nasal polyposis, Severe septal deviation preventing access to the olfactory cleft, Active acute or chronic rhinosinusitis, Recent epistaxis or bleeding-prone nasal mucosa, Nasal lesions, ulcers, tumors, or recent nasal surger
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliera di Perugia
Perugia, 06129, Italy
-
Centro Neurolesi Bonino Pulejo
Messina, Messina, 98124, Italy
-
Istituto Neurologico Carlo Besta
Milan, Milano, 20133, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Spinal cord stimulation put to the test for Parkinson's freezing of gait
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades